TMLI as Conditioning Regimen for Haploidentical HCT in Myelodysplasia or Acute Leukemia

Phase 2, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 100 days and Graft-versus-host disease-free relapse-free survival at 2 years. Started Feb 2020; status: active, not recruiting.